Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and plx4032

irinotecan has been researched along with plx4032 in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (66.67)24.3611
2020's3 (33.33)2.80

Authors

AuthorsStudies
Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H1
Bautista, F; Dufour, C; Geoerger, B; Grill, J; Lacroix, L; Minard-Colin, V; Paci, A; Valteau-Couanet, D; Varlet, P1
Imyanitov, EN; Iyevleva, AG; Krasnova, ME; Mitiushkina, NV; Raskin, GA; Silkin, SV; Sokolenko, AP; Startsev, SS1
Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG1
Atkins, J; Bellido, J; El Osta, B; Fogelman, D; Fu, S; Hong, DS; Huang, H; Janku, F; Kee, B; Kopetz, S; Lanman, R; Meric-Bernstam, F; Morris, VK; Overman, MJ; Piha-Paul, S; Shureiqi, I; Sommer, N; Sorokin, AV; Subbiah, V; Tarcic, G; Tsimberidou, AM1
Dai, WP; Jiao, XD; Li, XN; Liu, K; Qin, BD; Qin, WX; Sun, L; Wang, MM; Wang, Z; Ye, CY; Yuan, LY; Zang, YS1
Bao, H; Chen, XX; Chen, ZG; Du, ZM; Hu, MT; Huang, ZY; Jin, Y; Ju, HQ; Li, YH; Ren, C; Shao, Y; Wang, DS; Wang, F; Wang, FH; Wu, SX; Wu, X; Xu, RH; Ye, LF1
Chang, W; Fu, J; Lin, Q; Lv, Y; Tang, W; Wang, G; Xu, J; Xu, Y; Zhang, T; Zheng, X; Zhu, Z1

Trials

1 trial(s) available for irinotecan and plx4032

ArticleYear
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 163

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proto-Oncogene Proteins B-raf; Vemurafenib

2022

Other Studies

8 other study(ies) available for irinotecan and plx4032

ArticleYear
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Cancer research, 2012, Feb-01, Volume: 72, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays

2012
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Cancer Vaccines; Child; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Doxorubicin; Drug Evaluation; Fatal Outcome; Ganglioglioma; Humans; Immunotherapy; Indoles; Infant; Irinotecan; Male; Mutation, Missense; Neoplasm Proteins; Point Mutation; Polyethylene Glycols; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Salvage Therapy; Sulfonamides; Temozolomide; Thalamus; Treatment Outcome; Vemurafenib

2014
Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.
    Journal of gastrointestinal cancer, 2016, Volume: 47, Issue:4

    Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholangiocarcinoma; Humans; Indoles; Irinotecan; Male; Mutation; Panitumumab; Sulfonamides; Vemurafenib

2016
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
    Nature medicine, 2016, Volume: 22, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calreticulin; Camptothecin; Cell Death; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Leucovorin; Mice; Panitumumab; Phagocytosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Unfolded Protein Response; Vemurafenib; X-Box Binding Protein 1

2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
    Cancer discovery, 2016, Volume: 6, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Mice; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib; Xenograft Model Antitumor Assays

2016
Drug Combo Beats Vemurafenib Alone for Colorectal Cancer.
    Cancer discovery, 2017, Volume: 7, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Indoles; Irinotecan; Mutation; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vemurafenib

2017
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2022, Volume: 65

    Topics: Cetuximab; Circulating Tumor DNA; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Vemurafenib

2022
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2023, Volume: 49, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Proto-Oncogene Proteins B-raf; Rectal Neoplasms; Vemurafenib

2023